EU Accepts Sanofi's Concessions to Settle Antitrust Probe Over Vaccine Marketing
By Adria Calatayud
The European Union's antitrust body said it accepted Sanofi's concessions to end a competition investigation into the French drugmaker's marketing campaign for a flu vaccine.
The European Commission--the bloc's executive arm and competition enforcer--said Wednesday that Sanofi's offer to rectify the potential effects of its past messages on a rival flu shot made by Australia's CSL and refrain from any communication casting doubt about its performance would address its concerns. Those commitments will become legally binding for Sanofi, it added.
The commission launched a probe in June to assess whether Sanofi's efforts to promote its Efluelda flu vaccine in France and Germany breached competition rules, citing concerns they could amount to disparagement campaigns against CSL's Fluad.
Sanofi said at the time it was confident it had acted in full compliance with all applicable laws and regulation and that it was cooperating with EU authorities.
In August, the European Commission said it would seek feedback on commitments offered by the company to address its concerns.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
October 14, 2026 04:18 ET (08:18 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
5 Stocks to Sell for Tax-Loss Harvesting
33 Undervalued Stocks to Buy Before the Market Shifts Again
Undervalued by 15%, This Utilities Stock Could Be an Unexpected AI Winner
United States